Agenus (AGEN) Q4 2025 earnings summary

Executive summary

• BOT + BAL immunotherapy advanced to global Phase 3 trials for refractory MSS metastatic colorectal cancer, with early access programs expanding to over 30 countries and initial revenues recognized from these programs.

• France expanded reimbursed access to include metastatic ovarian cancer and sarcoma, broadening patient reach and clinical experience.

• Strategic collaboration with Zydus secured $91M upfront capital, dedicated U.S. biologics manufacturing, and a $20M contingent payment, strengthening the balance sheet and commercial readiness.

Financial highlights

• Recognized $4.2M in net revenue from early access programs in 2025, with $3.2M in Q4 alone.

• Other revenue, including non-cash royalty revenue, totaled $31.1M for Q4 and $14.4M for the full year.

• Operating loss was $10.6M for Q4 and $110M for the full year; net loss was $20.2M for Q4 and $3.1M for the full year.

Outlook and guidance

• Strategic priorities for 2026 include expanding patient access, advancing regulatory filings in the U.S. and EU, enrolling in the Phase 3 BATTMAN trial, and generating additional clinical data.